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Digital Cognitive Behavioral Therapy for Insomnia Promotes Later Health

Abstract

Methods: COVID impact, insomnia, general- and COVID-related stress, depression, and global health
were assessed in April 2020 in adults with a history of insomnia who completed a randomized
controlled trial of dCBT-I (n = 102) versus sleep education control (n = 106) in 2016-2017. Regression
analyses were used to evaluate the effect of intervention conditions on subsequent stress and
health during the pandemic.
Results: Insomnia symptoms were significantly associated with COVID-19 related disruptions, and
those previously received dCBT-I reported less insomnia symptoms, less general stress and COVIDrelated cognitive intrusions, less depression, and better global health than those who received sleep
education. Moreover, the odds for resurgent insomnia was 51% lower in the dCBT-I versus control
condition. Similarly, odds of moderate to severe depression during COVID-19 was 57% lower in the
dCBT-I condition.
Conclusions: Those who received dCBT-I had increased health resilience during the COVID-19
pandemic in adults with a history of insomnia and ongoing mild to moderate mental health
symptoms. These data provide evidence that dCBT-I is a powerful tool to promote mental and
physical health during stressors, including the COVID-19 pandemic.
Keywords: stress, COVID-19, insomnia, depression, CBT-I, engagement, prevention, primary care,
digital health
Clinical Trial: Sleep to Prevent Evolving Affective Disorders; NCT02988375
(https://clinicaltrials.gov/ct2/show/NCT02988375)
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Study Objectives: Stressful life events contribute to insomnia, psychosocial functioning, and illness.
Though individuals with a history of insomnia may be especially vulnerable during stressful life
events, risk may be mitigated by prior intervention. This study evaluated the effect of prior digital
cognitive-behavioral therapy for insomnia (dCBT-I) versus sleep education on health resilience
during the COVID-19 pandemic.

Statement of Significance
This study examines the role of insomnia treatment in promoting resilience
during the COVID-19 pandemic. Results indicate people who received treatment years

exposure to COVID-19. The protective effects were also observed in depression and
global health.
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prior to the pandemic exhibited better insomnia and stress regulation despite similar

Introduction

Insomnia is a common and debilitating consequence of pandemic-related stress and schedule
disruption,3,9 and thus is of particular relevance during the COVID-19 pandemic. Although sleep
disruption can be a symptom of mental disorders, insomnia is increasingly considered a distinct and
comorbid disorder that warrants sleep-focused intervention.12–14 In addition to the suffering
associated with sleeplessness, insomnia triggers and/or exacerbates other mental health
problems,15–18 adds to distress and impairment when comorbid with mental illness,19–24 and
frequently persists after other symptoms of mental illness have remitted.25–29 This may be because
insomnia further sensitizes the stress system,30 leading to increased perceptions of life events as
more stressful31 and reduced resilience and recovery from stress.32
Although the evidence clearly supports managing and treating insomnia, it is also important to
examine how resilience can be promoted to prevent insomnia in response to new stressors. This
aligns with the growing call for a focus on prevention to increase impact for public health.33,34
Insomnia is an ideal target for prevention because it is well-defined, highly modifiable, and is a
robust risk factor for a range of psychiatric and medical morbidities.18,35,36 Moreover, the treatment
effects of Cognitive Behavioral Therapy for Insomnia (CBT-I) – the recommended first-line treatment
for chronic insomnia 37,38 – extend beyond insomnia to reduce the incidence, severity, persistence,
and recurrence of non-sleep mental and physical health problems. For example, CBT-I has been
shown to reduce non-sleep symptoms of depression and anxiety,39,40 non-sleep focused
rumination,41 chronic pain,42 as well as global health and quality of life.43 Together, these results
suggest that the effects of insomnia treatment may strengthen health across multiple domains to
promote resilience against future stressors. Indeed, we have shown that CBT-I reduced the one-year
incidence of depression by 50%, even when delivered digitally (dCBT-I) for increased accessibility.44
The overarching aim of the present study was to examine resilience in the sleep and stress systems
during the COVID-19 pandemic. As individuals with a history of insomnia disorder are at higher risk
of experiencing stress and insomnia symptoms during the COVID-19 pandemic, we were interested
in evaluating if those who had previously received insomnia treatment experienced more resilience.
To accomplish this aim, we invited participants from a 2016-2017 dCBT-I intervention trial to
complete measures of COVID impact, symptoms of insomnia, general- and COVID-related stress, and
depression and physical health. Participants in this trial predominantly resided in the Detroit
metropolitan area, which was disproportionately impacted by the COVID-19 pandemic. Our central
hypothesis was that individuals who previously received dCBT-I would show more health resilience
during the COVID-19 pandemic compared to individuals who received sleep education. Our first
specific hypothesis was that insomnia symptoms during the pandemic would be less severe in those
who previously received dCBT-I compared to those in the sleep education control condition. Our
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The 2019 coronavirus disease (COVID-19) pandemic has had health consequences that extend wellbeyond symptoms of the virus. Mental health problems, including symptoms of insomnia,
posttraumatic stress, and depression are already being observed in the context of COVID-191–5 and
have been documented during previous epidemics (e.g., SARS, MERS).6 As a consequence, COVIDrelated disability and mortality will include impairment from mental illness, which is already a
leading contributor to global disease burden.7 Public health interventions that aim to reduce COVIDrelated disease burden should include interventions to promote mental resilience.8–11

second specific hypothesis was that those who previously received dCBT-I would report less stress
during the pandemic compared to participants in the control condition. Our third hypothesis was
that participants who previously received dCBT-I would have lower depressive symptoms and better
global health compared to the control group.

Participants for this study were recruited from a previous randomized controlled trial
(NCT02988375) testing the efficacy of self-guided dCBT-I compared to a sleep education control in
treating insomnia71 and preventing incident depression.44 Participants in the SPREAD trial were
enrolled between 2016 and 2017, with a final sample of 358 in the dCBT-I condition and 300 in the
control condition. Those in the dCBT-I condition completed 6 sessions of self-guided dCBT-I, which
were directed by an animated “virtual therapist” who reviews and guides progress with the
participant. Individuals randomized to the online sleep education condition received six weekly emails based on the NIH guide to healthy sleep (National Institutes of Health, 2011). Eligibility for the
SPREAD trial was assessed via an online screener. This approach has been validated against clinicianadministered diagnostic interviews.72,73 Eligible participants met criteria for insomnia disorder based
on the DSM-5: insomnia symptoms present on 3 or more days per week, with significant distress or
impairment, and of at least 3 months duration. Participants were excluded from the SPREAD trial if
they reported a diagnosis of any untreated sleep disorders other than insomnia (e.g., obstructive
sleep apnea, restless legs, narcolepsy, etc.), and bipolar or seizure disorders. Because the SPREAD
trial included a depression prevention aim, individuals with high depression chronicity (self-reported
daily or near daily depressed mood and anhedonia) were excluded (see Cheng et al., 201871 for
addition details).
All 658 participants in the SPREAD trial were eligible for this follow-up study. The recruitment plan
targeted enrollment at 200 participants, which would achieve sufficient power (0.8) to detect a
moderate effect size for each hypothesis test. Email invitations were sent during the last week of
April 2020, five weeks into the Michigan state-wide stay-at-home order, with approximately 40,000
cases and 3800 deaths across the state. Enrollment was closed in the first week of May when the
targeted sample size was achieved. The final sample included 208 participants (dCBT-I: n = 102;
control: n = 106).

Measures of interest
Once enrolled, participants completed an online survey that assessed for COVID impact, insomnia,
stress, and health during the COVID-19 pandemic.
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Methods

Impact of the COVID-19 pandemic. Direct impact from the COVID-19 was measured

The impact of the COVID-19 pandemic on daily life was measured using the Coronavirus Impact Scale
(CIS). The CIS was made available through a collection of COVID-19 Research Tools assembled by the
Office of Behavioral and Social Sciences Research at the National Institutes of Health.75 The CIS rates
the degree of change across multiple domains of daily life on a four-point Likert scale (0 = No
change, 1 = Mild, 2 = Moderate, 3 = Severe) across 11 items. Domains assessed included routines;
income/employment; access to food, medical care, and mental treatment; access to social support;
pandemic related stress; familial stress and discord; and diagnoses of coronavirus. One open-ended
item allowed free text responses to capture other ways in which daily life may have been impacted
by the COVID-19 pandemic. Given the recency of the pandemic, there is no psychometric data
available for the CIS.

Insomnia
. Symptoms of insomnia were assessed using the 7-item Insomnia Severity Index (ISI),76 with higher
scores indicating increased insomnia severity (range 0 – 28). A score of 15 or greater on the ISI was
used as a threshold for moderate to severe insomnia. Because the ISI is not designed to assess
insomnia in response to a specific event, another question was included to assess the impact of the
COVID-19 pandemic on sleep using a 5-point Likert scale. The prompt was, “How much impact did
the COVID-19 pandemic have on your sleep?”, and responses ranged from Not at all (0) to Very much
(4). Results from this item was examined independently and was not incorporated into the ISI.

Stress. Both general stress and stress specific to the COVID-19 pandemic were assessed.
General stress was measured using a validated single-item instrument.77,78 The prompt for this
instrument was “Stress means a situation in which a person feels tense, restless, nervous or anxious
or is unable to sleep at night because his/her mind is troubled all the time. Do you feel this kind of
stress these days?” Response on this instrument was on a 5-point Likert scale ranging from never (0)
to always (4).
Stress and trauma specific to the COVID-19 pandemic was assessed using the 22-item Impact of
Events Scale79 (IESCOVID-19). The IES measures the amount of distress associated with a specific event.
Though the IES allows individuals to specify the event in question, we predetermined “the COVID-19
pandemic” in the instructions as we were interested in measuring stress specifically associated with
the COVID-19 pandemic. The total score on the IES ranges from 0 to 88, with a score of 24 indicating
clinically significant impairment. The IES score comprises three component scores: cognitive
intrusion, avoidance, and hyperarousal. Both cognitive intrusion and avoidance describe
psychological experiences of stress prior to assimilation of the trauma, the cognitive intrusion
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using the same framework as the Life Events Checklist.74 Three prompts were included: 1) Exposure
to the coronavirus, 2) Life-threatening illness or injury related to the coronavirus, 3) Severe human
suffering related to the coronavirus. Participants were asked if those items happened to them in six
different ways: 1) it happened to them, 2) they witnessed it happening to someone else, 3) they
learned about it happening to a close friend or family member, 4) they were exposed to it as part of
their job, or if 5) they are unsure or 6) it does not apply to them. Direct impact from the novel
coronavirus was operationalized as any endorsement of responses 1 through 4 on at least one of the
three items described.

reflecting repeated thoughts about the trauma, and avoidance reflecting effortful avoidance of
reminders of the trauma. The third component describes physiological hyperarousal as a cluster of
PTSD symptoms.

Health Outcomes. In addition to insomnia symptoms, we also assessed for other

the 16-item self-report Quick Inventory of Depressive Symptomatology (QIDS-SR16),81 a
reliable and validated instrument for measuring depression symptoms commonly used
in clinical trials. Scores on the QIDS-SR16 range from 0 to 27, and a score greater than 10
reflects moderately severe symptoms. Global health was assessed via the Global-10 from
the NIH Patient-Reported Outcomes Measurement Information System (PROMIS).82 The
Global-10 assesses general domains of health and functioning including overall physical
health, mental health, and overall perceived quality of life. The Global-10 has two
components: Global Physical Health (GPH), and Global Mental Health (GMH). Both
components are normed on a T-score distribution, with the population mean at 50 and a
standard deviation of 10 points. Higher scores on the Global-10 and its components
indicate better health.
Analytical Approach
The hypotheses were tested with ordinary least squares regression models with Condition (dCBT-I,
sleep education control [reference group]) as the independent variable. All analyses controlled for
pre-treatment insomnia severity as a measure of insomnia risk. The first hypothesis was tested using
standardized scores from the ISI as the dependent variable. Because the dCBT-I condition reported
less insomnia after treatment compared to those in the control condition, a sensitivity analysis was
conducted in a subsample of individuals who reported symptom resolution (ISI < 8) at one-year
follow-up. This analysis enabled more robust inference regarding symptom resurgence during the
COVID-19 pandemic. To distinguish symptom resurgence from normative variations in sleep
(especially given the context of a global pandemic), symptom resurgence was operationalized as
moderate to severe symptoms (ISI ≥ 15) in those who previously reported symptom resolution. The
second hypothesis was tested using standardized general stress and IESCOVID-19 total and component
scores as the dependent variables via regressions models. The third hypothesis was tested using
standardized scores on the QIDS-16SR and the Global-10 component t-scores as the dependent
variables in regression models. To examine the robustness of results, effect sizes were also
contrasted between those who were and were not directly impact by the coronavirus.
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health outcomes including depression and global health. Depression was assessed using

Results
The final sample included 208 (dCBT-I: n = 102; control: n = 106; see Table 1 for a summary of
sample characteristics by group). During the COVID-19 pandemic, 67.3% of the sample reported
direct impact from the coronavirus, and 26.4% reported living alone during the shelter-in-place
orders. On average, the sample reported mild disruptions across the domains assessed on the CIS (M
= 1.1 ± 0.03 SE). The three domains most impacted by COVID-19 included daily routines (M = 2.2 ±
0.06 SE), stress (M = 1.7 ± 0.06 SE), and social support (M = 1.6 ± 0.06 SE). The control and dCBT-I
condition reported similar levels of disruption due to COVID-19. However, despite similar levels of
disruption due to COVID-19, those who previously received the sleep education control reported
that the pandemic had a larger impact on their sleep (M = 2.0 ± 0.12 SE) compared to those who
received dCBT-I (M = 1.5 ± 0.11 SE), p = .009.

[ Table 1 ]

Insomnia during COVID-19
The average ISI score was 12.1 ± 0.48 SE (see Figure 1 for ISI by group), with 34.1% reporting
moderate to severe insomnia symptoms (ISI ≥ 15). Adjusting for baseline insomnia symptoms, ISI
scores during the pandemic were significantly associated with the impact of the coronavirus
assessed by CIS scores, B = 0.52 ± 0.05 SE, p < .001 (see Figure 1). Similarly, those who reported that
the pandemic had a larger impact on their sleep also exhibited more severe ISI scores, B = 0.83 ±
0.05 SE, p < .001. Together, these data indicate a robust association between insomnia symptoms
and the COVID-19 pandemic.
Consistent with our hypothesis, results also revealed that those who previously received dCBT-I
exhibited less severe insomnia symptoms during the pandemic, b = -2.9 ± 0.8 SE, p = .001 (B = -0.41),
indicating that ISI scores were approximately 3 points lower in the dCBT-I group compared to the
control group during the pandemic. The effect size of dCBT-I on insomnia symptoms during COVID19 were comparable between individuals directly impacted by the coronavirus (B = -0.43) compared
to those who were not directly impacted (B = -0.37). Sensitivity analysis also revealed that odds of
resurgent moderate to severe insomnia during COVID-19 in those who previously reported symptom
resolution (ISI < 8 at one-year follow-up) was 51% lower in those who received dCBT-I relative to
control, OR = 0.49, 95% CI [0.25, 0.96], p < .001.
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Given that research conducted during a global pandemic may be vulnerable to selection bias,83,84 we
utilized sampling weights for all analyses to mitigate differences in the probability of selection into
the study relative to the original population of SPREAD trial participants. Sampling weights equal to
the reciprocal of the selection probability in each condition were utilized to balance the probability
of selection based on insomnia severity following treatment in the SPREAD trial. Insomnia severity
categories were non-clinically significant (ISI ≤ 7), subthreshold (ISI > 7 and ≤ 14), and clinically
significant (ISI ≥ 15). The final weighted mean (9.8 ± 5.7 SD) did not differ significantly from the
population mean (10.4 ± 5.8 SD), suggesting that selection bias was likely minimal.

[ Figure 1 ]

Stress during COVID-19

In terms of COVID-19 specific stress, the sample reported a mean IESCOVID-19 score of 26.5 ± 1.0 SE
(see Figure 2 for component scores by condition). Those who previously received dCBT-I reported
lower total IESCOVID-19 scores compared to the control condition, b = -4.1 ± 1.9 SE, p = .03. Analyses of
the IESCOVID-19 component scores revealed a significant effect for cognitive intrusion, b = -0.3 ± 0.1 SE,
p = .03 (B = -0.30), a marginal effect for hyperarousal, b = -0.2 ± 0.1 SE, p = .08 (B = -0.23), but no
significant effect for avoidance (p = .23). The buffer effect of dCBT-I against cognitive intrusion was
comparable for those who were directly impacted by the coronavirus (B = -0.31) than those who
were not directly impacted (B = -0.26).
[ Figure 2 ]

Health during COVID-19
Depression. The sample reported a mean QIDS-SR16 score of 10.6 ± 0.3 SE (see Figure
3 for means by condition). Those who previously received dCBT-I also showed lower depressive
symptoms, b = -1.3 ± 0.5 SE, p = .011. Importantly, the odds of moderate to severe depressive
symptoms during COVID-19 was 57% lower in those who had received dCBT-I compared to those
who received sleep education, OR = 0.43, 95% CI [0.30, 0.61], p < .001.

Global Health. The sample’s average Global Physical Health (GPH) and Global Mental
Health (GMH) t-scores were 45.7 ± 0.5 SE and 43.4± 0.6 SE, respectively (see Figure 3 for means by
condition). Results from the multivariate regression indicated that who previously received dCBT-I
reported better global health, F(2,204) = 3.77, p = .02.
Consistent with the other results, those who previously received dCBT-I exhibited better
Global Physical Health, b = 2.76 ± 1.01 SE, p = .006. As the subscales are normed on a T-score
distribution (M = 50, SD = 10), this indicates that while both groups show GPH scores within a SD of
the population mean, the deviation from population mean in the control group (5.9 points) was
approximately two-fold higher that of the dCBT-I group (3.1 points), indicating better global physical
health in the dCBT-I group relative to the control group. In contrast, group differences on the GMH
1

Results were not substantively different when sleep items were removed from the QIDS-SR16.
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The sample reported a mean general stress score of 2.3 ± 0.07 SE (see Figure 2 for means by
condition). Consistent with our hypothesis, those who previously received dCBT-I also demonstrated
a trend of less overall stress levels during the COVID-19 pandemic compared to the control
condition, b = -0.2 ± 0.1 SE, p = .055 sample (B = -0.25), despite similar exposure to disruptions due
to COVID-19. The buffer effect of dCBT-I on stress was larger for those reporting direct impact by the
coronavirus (B = -0.36) compared to those who were not directly impacted (B = -0.09).

component did not achieve statistical significance, b = 1.46 ± 1.10 SE, p = .18 (effect size corresponds
to a Cohen’s d of 0.15).

[ Figure 3 ]

Discussion
The results of this study support the overall hypothesis that dCBT-I treatment increases health
resilience during the COVID-19 pandemic. Consistent with other early reports of COVID-related
health outcomes,3,5 COVID-related disruptions in daily life were associated with insomnia symptoms.
At the time of data collection, southeast Michigan was a significant hotspot of COVID-19 cases
(approximately 40,000 cases and 3800 deaths) and it is therefore not surprising that most of the
participants in this sample reported that the COVID-19 pandemic had a direct impact on their lives.
On average, the sample also reported insomnia symptoms, moderate overall stress, clinically
significant COVID-related stress, moderate depressive symptoms, and moderate overall health.
Considered together, these results provide evidence that dCBT-I promotes health resilience in an
adult population with a history of insomnia and ongoing mild to moderate psychiatric symptoms.
Results showed that, relative to a sleep education intervention, adults who completed dCBT-I in
2016-2017 had lower symptoms of insomnia, lower general stress and COVID-related cognitive
intrusions (intrusive thoughts, feelings, and imagery; nightmares; dissociative-like re-experiencing),
lower depressive symptom severity, and better global health. Moreover, these data suggest that
dCBT-I helped build resilience during the COVID-19 pandemic. Relative to sleep education, dCBT-I
prevented a resurgence of clinically significant insomnia during the pandemic by 50%. Additionally,
the odds of moderate to severe depression in those who received dCBT-I was almost 60% lower than
the sleep education group. These health outcomes were observed in April 2020 of the COVID-19
pandemic, 3-4 years after treatment completion, suggesting that dCBT-I offers long-lasting
protection across multiple health domains and in the context of a global health threat. In light of the
pressing mental health needs associated with the COVID-19 pandemic, the significance of these
results is difficult to overstate. They add to a growing literature suggesting that behavioral insomnia
treatment improves health, 39,59,66,68–70 and provide the first prospective evidence that dCBT-I
increases health resilience during later stressors — in this case the COVID-19 pandemic.
This study was not designed to examine mechanisms of insomnia treatment; however, there are a
number of potential mechanisms by which dCBT-I may promote health resilience. Hyperarousal
models posit that insomnia may be related to disruptions in biological (autonomic and central
nervous system functioning85–88) and cognitive systems (cognitive arousal, worry and rumination,
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Given that the sample was powered to detect moderate effect sizes, additional analyses were
conducted to examine the odds of low GPH and GMH scores, defined as scores half a standard
deviation lower than the population norm (t-score ≤ 45, corresponding to a Cohen’s d of 0.5). These
variables were then used in a logistic regression with Condition as the predictor of interest. Results
indicated that the odds of reporting low GPH and GMH was 58% and 42% lower in the dCBT-I group
relative to the control group, respectively (see Figure 3), GPH: OR = 0.42, 95% CI [0.29, 0.62], p =
.002; GMH: OR = 0.58, 95% CI [0.42, 0.82], p < .001.

It is now evident that the COVID-19 pandemic will likely be a long-term stressor for many,
particularly as the temporary support systems begin to subside (e.g., federal stimulus payments,
enhanced unemployment), and as additional waves recur. This has potential to perpetuate a
compounding cascade of negative consequences for mental and physical health, particularly as
chronic stress increases allostatic load and erodes biological and emotional-cognitive systems .100 As
such, it is also important to consider the role of insomnia treatment during the COVID-19 pandemic,
particularly as untreated insomnia is both common and debilitating. Epidemiological data prior to
the pandemic indicates that approximately 9% of adults within the United States report daily or near
daily insomnia symptoms,101 and this number may have increased due to COVID-19. Additionally, the
economic burden of insomnia is significant,102–106 and is worsened by its medical comorbidities.107,108
Together, these data suggest that the prevalence and costs of insomnia are likely to increase as the
COVID-19 pandemic continues.3,9 dCBT-I offers an accessible (self-paced, geographically
unrestricted, low cost), acceptable, and efficacious intervention for insomnia and mental health.39,109
Our data suggest that we could capitalize on the promise of dCBT-I to promote mental and physical
health during the COVID-19 pandemic.
This study has both strengths and limitations that impact the significance of these results. Strengths
of this study include the assessment of long-term effects of dCBT-I during a natural and chronic
stressor that will have a myriad of major implications for public health. Most of the sample reported
direct impact from the coronavirus, providing face validity to our claim that dCBT-I improves health
resilience. The study sample (n = 208) allowed for adequate power to detect moderate effects of
dCBT-I on health outcomes. Furthermore, the study included sleep education as an active
comparison condition to control for non-specific effects of intervention effort and attention on
health outcomes. The sample was also heterogeneous with regard to race/ethnicity and
socioeconomic status, providing greater confidence in the generalizability of the results.
Limitations of this study include potential selection bias considering the context of a global
pandemic; however, the analyses utilized sampling weights to mitigate this limitation. Additionally,
the measure of general stress included sleep disturbance as part of the phenomenology of stress

Downloaded from https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsaa258/6010120 by Henry Ford Hospital user on 22 December 2020

and emotional distress58,89–91) that support energy mobilization.92–96 CBT-I can mitigate these
underlying mechanisms, 41,59,97,98 especially as the components of CBT-I (e.g., cognitive restructuring,
relaxation, sleep hygiene) are designed to target the arousal system as a barrier to sleepiness around
the sleep period. Indeed, our results suggest that those who previously completed dCBT-I
experienced less stress, and cognitive intrusion and hyperarousal on the IESCOVID-19. Additionally,
research should also further examine different mechanisms by which insomnia contributes to
adverse outcomes relevant to the COVID-19 pandemic, such as stress and trauma-related symptoms
(e.g., vigilance to threat) versus depressive symptoms (e.g., hedonic processing). Different types of
insomnia (e.g., short sleep and non-restorative phenotypes) may also differentially impact biological
and cognitive-emotional systems. For example, whereas medial prefrontal cortex functioning has
been implicated in the relationship between non-restorative sleep and later depressive symptoms, it
does not have a significant role in the relationship between nocturnal insomnia symptoms and later
depressive symptoms.99 Understanding the mechanisms by which insomnia contributes to different
types of mental health problems (multifinality), or how different types of insomnia contribute to the
same mental health problem (equifinality) may facilitate personalized and mechanistically-specific
treatment approaches.

Conclusion
This study examined the role of prior treatment of insomnia with digital CBT-I (dCBT-I) on health
resilience during the COVID-19 pandemic. Results demonstrated that those who received dCBT-I
reported less insomnia, stress, depression, and better global physical health compared to those who
received a sleep education control. Indeed, the risk of clinically significant insomnia and depression
during the pandemic was reduced approximately by half in the dCBT-I group relative to the control
group. Future research should examine the mechanisms by which insomnia treatment may enhance
resilience, and the role of dCBT-I in mitigating the adverse health consequences of the COVID-19
pandemic.
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response. The sample size, although large enough to detect moderately large effects of interest, was
not sufficient to detect potential moderators of dCBT-I outcomes (e.g., COVID-exposure, COVIDrelated stress, race, socioeconomic status) in primary hypothesis tests. We also did not design the
study to examine mechanisms by which dCBT-I may differentially predict individual health outcomes
(i.e., insomnia symptoms, COVID-related intrusions, depressive symptoms, global physical health).
Finally, data collected in April 2020 may not represent the effects of dCBT-I later in the course of the
COVID-19 pandemic. Additional follow-up assessments could help establish the persistence of
benefit from dCBT-I and the relationship between mental health symptoms and COVID-19 chronicity
and impact over time.
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Tables and Figure Captions
Figure 1. Insomnia symptom severity during the COVID-19 pandemic. Panel A: Bubble chart of the weighted association
between insomnia symptoms and disruptions to daily life due to COVID-19 (r = 0.60). Larger points indicate stronger
***
weighting. Panel B: Estimated marginal means for insomnia severity by group. Error bars represent one standard error. p
**
*
†
≤ .001, p ≤ .01, p ≤ .05, p < .10

Figure 3. Odds ratios of clinical outcomes in the dCBT-I relative to the control group. Resurgent Ins = resurgence of
moderate to severe insomnia during COVID-19 in individuals who showed symptom resolution following the SPREAD trial;
Mod-Sev Dep = moderate to severe depression on the Quick Inventory of Depressive Symptomatology (QIDS-SR16); Low
GPH = Global Physical Health scores below half a standard deviation of the population norm; Low GMH = Global Mental
Health scores below half a standard deviation of the population norm. Error bars represent the 95% confidence intervals.
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Figure 2. Estimated marginal means for stress by group. Panel A: General stress; Panel B: COVID-19 specific stress as
***
**
measured on the Impact of Events Scale specific to COVID-19. Error bars represent one standard error. p ≤ .001, p
*
†
≤ .01, p ≤ .05, p < .10

Table 1. Baseline sample characteristics by group. dCBT-I = digital Cognitive Behavioral Therapy for Insomnia; CIS =
Coronavirus Impact Scale. No group differences were detected at p < .05.

Control (n=106)

White
Black
Other
2019 Household Income
Very low (<15k)
Low (<35k)
Middle (<75k)
High (≥75k)
Married/Partnered
Living alone
Pre-treatment ISI (M ± SD)
COVID-19 direct impact
CIS (M ± SD)

44.7 ± 14.2
84.0%

44.6 ± 14.1
72.5%

68.8%
27.4%
3.8%

73.5%
18.6%
7.8%

9.4%
23.6%
34.0%
33.0%
48.1%
28.3%
17.0 ± 4.12
67.0%
12.1 ± 5.3

5.0%
19.6%
43.1%
32.4%
59.8%
24.5%
18.0 ± 3.8
67.6%
11.4 ± 4.3
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Age (M ± SD)
Sex (Female)
Race

dCBT-I (n=102)

Figure 1
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Figure 2
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Figure 3
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